Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors

Giovanna Del Vecchio Blanco, Giampiero Palmieri, Diana Giannarelli, Vincenzo Formica, Ilaria Portarena, Antonella Nardecchia, Edoardo Troncone, Michela Benassi, Emilia Giudice, Alessandro Anselmo, Giuseppe Tisone, Mario Roselli, Giovanni Monteleone & Omero Alessandro Paoluzi


To link to this article: https://doi.org/10.1080/00365521.2021.1880628
Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors

Giovanna Del Vecchio Blanco, Giampiero Palmieri, Diana Giannarelli, Vincenzo Formica, Ilaria Portarena, Antonella Nardecchia, Edoardo Troncone, Michela Benassi, Emilia Giudice, Alessandro Anselmo, Giuseppe Tisone, Mario Roselli, Giovanni Monteleone and Omero Alessandro Paoluzi

Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Anatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Biostatistical Unit, Regina Elena Institute-Hospital Physiotherapy Institutes, Rome, Italy; Oncology Unit, University of Rome Tor Vergata, Rome, Italy; Radiotherapy Unit, Department of Oncohematology, University of Rome Tor Vergata, Rome, Italy; Transplant Surgery Unit, Department of Surgery, University of Rome Tor Vergata, Rome, Italy

ABSTRACT

Background and aim: Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is influenced by several factors, primarily operator expertise. Formal training in EUS-FNA, as suggested by the European Society of Gastrointestinal Endoscopy and the American Society for Gastrointestinal Endoscopy guidelines, is not always available and is often expensive and time-consuming. In this study we evaluate factors influencing the diagnostic accuracy of pancreatic EUS-FNA.

Methods: In a retrospective study, 557 consecutive EUS-FNAs were evaluated. Several variables relating to the procedures were considered to calculate the EUS-FNA performance over eight years.

Results: A total of 308 out of 557 EUS-FNAs were selected. Overall sensitivity of EUS-FNA was 66% (95% CI: 60.8–71.8), specificity 100%, and diagnostic accuracy 69% (95% CI: 64.0–74.4). An increase in diagnostic accuracy was observed to >90% using a new fine-needle biopsy (FNB) needle and in the case of simultaneous sampling of primary and metastatic lesions. Diagnostic accuracy >80% was observed after 250 procedures, in the absence of rapid on-site cytopathological examination (ROSE). Multivariate logistic regression analysis confirmed that the FNB needle, operator skill, and double EUS-FNA sampling are associated with high diagnostic accuracy.

Conclusions: The learning curve for EUS-FNA may be longer and a considerable number of procedures are needed to achieve high diagnostic accuracy in the absence of ROSE. However, the use of FNB needles and the simultaneous sampling of primary and metastatic lesions can rapidly improve the diagnostic accuracy of the procedure.

Introduction

Endoscopic ultrasound (EUS) is a diagnostic technique combining endoscopic viewing and ultrasonography imaging. EUS is used worldwide for diagnosing and staging several kinds of gastrointestinal, mediastinal, and perirectal space malignancies [1,2] as it allows a detailed analysis of the peritoneal wall of the digestive tract and surrounding organs. The major advantage of this technique is the ability to collect tissue from a lesion suspected to be malignant by EUS-guided fine-needle aspiration (EUS-FNA). EUS-FNA has proven to be effective for the diagnosis of several types of primary or metastatic tumors [3–6], biliopancreatic and abdominal/mediastinal lymph nodes mass lesions [7,8]. EUS-FNA is generally safe; rare complications after this procedure can be self-limited bleeding from the needle insertion site, pancreatitis, and infection, which account for 0–2% of cases [9,10]. In patients with pancreatic mass, EUS-FNA is considered the method of choice for differential tissue diagnosis between a benign or malignant lesion, yielding extremely high sensitivity (85%–89%) and specificity (96%–99%) [2]. EUS-FNA is also helpful in choosing the most appropriate targeted therapy in a locally advanced or borderline resectable neoplasm on the pancreas and is often requested by the surgeon to confirm the diagnosis of malignancy before surgery.

Multiple factors influence the diagnostic accuracy of EUS-FNA in the differential diagnosis of pancreatic neoplasms, above all the size and location of the mass, and the presence of peritumoral desmoplastic stromal reaction or concomitant chronic pancreatitis. Some methodological innovations have been suggested to improve the diagnostic yield of EUS-FNA, such as increasing the needle gauge, modifying the needle tip, increasing the number of passes in the lesion, or modifying the sampling technique (standard versus stylet slow-pull suction, wet method, fanning method) [6,11–14].

There is general agreement that the diagnostic accuracy of EUS-FNA increases with operator experience, as it is an operator-dependent technique with a long learning curve.
Based on expert opinion, the American Society for Gastrointestinal Endoscopy (ASGE) suggests that clinical competence in all aspects of EUS may be achieved following at least 150 supervised EUS procedures. As a part of formal training, at least 75 supervised EUS procedures with pancreatic–biliary indication and 60 FNAs, including 25 of the pancreas, should be performed during the learning period [20]. Guidelines released by the European Society of Gastrointestinal Endoscopy (ESGE) recommend a minimum of 20 to 30 supervised EUS-FNAs in the presence of rapid onsite cytopathological examination (ROSE) to reach sufficient competency in this technique and sensitivity for pathological diagnosis up to 80% [21]. The importance of ROSE in increasing EUS-FNA diagnostic accuracy and reducing the number of passes needed to obtain sufficient tissue specimens is largely debated [22]. However, the presence of a cytopathologist in the endoscopy room may be limited for a number of practical reasons, such as local availability and high costs.

The present study aimed to evaluate EUS-FNA performance in the diagnosis of pancreatic and biliary neoplasms and to identify factors influencing diagnostic accuracy in the absence of ROSE.

**Patients and methods**

**Design of the study and population**

From January 2010 to May 2018, all clinical data regarding patients undergoing EUS-FNA for suspected biliary or pancreatic neoplasia in our Gastroenterology Unit were recorded in an electronic database at the time of the procedure. Data included were demographic information, indication for EUS-FNA, findings of previous diagnostic tests, and any active symptoms. The type and size of needle used, the sampling technique (standard versus stylet slow-pull suction), the number of passes, and the site of the lesion were also recorded. The final diagnosis was defined based on surgical specimens or the outcome at follow-up. All procedures were part of a standard diagnostic work-up and were performed after written informed consent was given. A multidisciplinary team established the diagnostic and therapeutic work-up of each patient. Patients with a final diagnosis different from pancreatic or biliary carcinoma, incomplete data, or an inconclusive result due to inadequate sampling, and in the event of high clinical suspicion of malignancy, EUS-FNA was repeated at least two times. In patients with metastasis, EUS-FNA included primary and secondary lesions in the same session, performing tissue sampling first in the metastasis and then in the primary lesion.

Tissue specimens were immediately put into formalin by releasing the syringe in a specimen bottle and adequacy of the material was evaluated in all patients by gross inspection by the operator, as ROSE was not available. Any complication during or following the procedure was recorded.

In all patients, the final diagnosis of malignancy was determined on the pathological findings of surgery specimens or clinical outcomes (i.e. death from the disease, radiological evidence by CT scan, or MRI of disease progression). The follow-up period was 252 days (range: 33–1355). Patients with no neoplastic findings on EUS-FNA were followed up for at least one year. EUS-FNAs with a conclusive diagnosis of malignancy were considered as true positive while those with no evidence of neoplasia or nuclear atypia as true negative samples. To evaluate the influence of the operator’s skills on the diagnostic accuracy of EUS-FNA, all procedures carried out during the study period were stratified over time in blocks of 50 (1–50, 51–100, 101–150, 151–200, 201–250, >250).

**EUS-FNA technique**

All procedures were performed by a single operator (DVB.G.), a gastroenterologist skilled in digestive endoscopy, who had undergone a training period in a center with a high volume of EUS procedures. During the traineeship, 200 EUS procedures including EUS-FNA were observed. Having carried out at least 250 diagnostic EUS procedures and acquired a good level of competence in linear EUS, the operator started performing EUS-FNA without supervisor. Subsequently, she attended further live EUS courses and international EUS meetings to gain further experience in interventional EUS.

All EUS-FNAs were performed with the patient recumbent in the left lateral position, under intravenous conscious or deep sedation with midazolam plus fentanyl or propofol. Vital signs, including heart rate, blood pressure, and partial pressure of oxygen (PaO₂) in the blood, were continuously monitored during the procedure and in the three hours following. Outpatients were discharged when a normal consciousness state and physical ability were fully recovered. A linear array echoendoscope equipped with a 7.5 MHz transducer (GF-UCT140 or GF-UCT180 Olympus, Tokyo, Japan) was used for diagnosing and staging the lesions. EUS-FNAs were carried out using a 19-, 22-, or 20-gauge needle (EchoTip ProCore®, Wilson-Cook Medical Inc, Winston-Salem, NC, USA; Expect™ or Acquire™, Boston Scientific, Marlborough, MA, USA: Shark Core™ FNB Medtronic, Minneapolis, MN, USA) for trans-duodenal and trans-gastric sampling. The needle was inserted through the working channel of the echoendoscope and advanced into the target lesion under real-time EUS imaging. During the study period, the suction technique changed from standard, with a 10-mL syringe attached to the proximal end of the needle, to the slow-pull technique. The needle was moved back and forth within the lesion for a minimum of two to a maximum of five times. If the pathologist returned a negative or inconclusive result due to inadequate sampling, and in the event of high clinical suspicion of malignancy, EUS-FNA was repeated at least two times. In patients with metastasis, EUS-FNA included primary and secondary lesions in the same session, performing tissue sampling first in the metastasis and then in the primary lesion.

**Histological evaluation**

Specimens were embedded in paraffin and sections stained with hematoxylin–eosin. Information regarding clinical history, including a description of the target lesion and the results of relevant diagnostic tests, was sent to the pathologist at the time of tissue sample submission.
Statistical analysis

Performance of EUS-FNA was evaluated according to the location of the lesion (pancreatic head, body, tail), needle size (19-, 20-, 22-gauge), number of passes (1–2, 3–4, 5–6), needle type, site of the lesion (primary and metastatic lesion), and operator skill (based on the number of procedures performed). All these factors were considered as variables potentially influencing diagnostic accuracy and their weight was evaluated by a logistic regression model. Variables were selected using a stepwise forward method based on likelihood ratio and remove and enter limits were set to 0.075 and 0.10, respectively, to better describe the possible associations. All statistical analyses were calculated using IBM SPSS ver. 21.0 statistical software.

Results

During the study period, 308 out of 557 EUS-FNAs were performed in 283 consecutive patients, 151 males, and 132 females, with a mean age of 66 years (range: 23–87), the remaining 249 procedures were excluded from the analysis as performed for indications other than biliopancreatic diseases. The final diagnosis was solid pancreatic neoplasm in 253 patients, cystic pancreatic neoplasm in eight patients, liver primary or metastatic neoplasm of previously diagnosed tumors in five patients, and cholangiocarcinoma in 17 patients.

Based on histological findings, the final pancreatic tissue diagnosis was pancreatic neuroendocrine tumor in 19 patients, pancreatic signet ring cell carcinoma in nine patients, poorly differentiated pancreatic carcinoma in 142 patients, B-cell lymphoma in two patients, pancreatic metastasis from previous kidney carcinoma in four patients, pancreatic metastasis from prostate carcinoma in one patient, and previous lung cancer in one patient.

Forty-eight EUS-FNAs were carried out using a 19-gauge needle. A total of 223 EUS-FNAs were carried out using a 22-gauge needle; 42 of these 223 procedures were performed using a new fine-needle biopsy (FNB) needle during the final year of the study. EUS-FNAs were performed using a 25-gauge needle in five cases and 22- plus 25-gauge needles at the same time in the remaining cases. The number of passes in each lesion was initially 4–5 (30% of cases) and decreased to three during the last three years of the study period.

At the end of the analysis, 188 samples were categorized as true positive (60%), 26 samples as true negative (9%), and 94 samples as not diagnostic (31%), with an overall EUS-FNA sensitivity, specificity, and diagnostic accuracy of 66.3% (95% CI: 60.8–71.8), 100%, and 69.2% (95% CI: 64.0–74.4), respectively.

The simultaneous sampling of primary and metastatic lesions and the repetition of EUS-FNA two times were found to increase diagnostic accuracy up to 97.9% (95% CI: 93.9–100) and 98% (95% CI: 93.9–100), respectively (Figure 1).

By stratifying data according to the site of the lesion, diagnostic accuracy was 72.3% in a neoplasm in the pancreatic head versus 75.2% in the pancreatic body and tail, and in other sites.

The majority of EUS-FNAs were performed with a 22-gauge needle with an overall sensitivity and diagnostic accuracy of 57.7% (95% CI: 50.1–65.2) and 61.7% (95% CI: 54.6–68.8), respectively. An improvement in EUS-FNA performance (sensitivity: 72.4% [95% CI: 62.3–82.4], diagnostic accuracy: 74.7% [95% CI: 65.3–84.1]) was obtained by changing the needle during the procedure from 22- to 25-gauge (Figure 1) in pancreatic head neoplasms. A considerable increase in sensitivity and diagnostic accuracy, up to ~90.5% (95% CI: 80.7–99.3), was observed in the case of EUS-FNB sampling (Figure 2).

To evaluate the influence of the operator’s skill on the performance of EUS-FNA, sensitivity and diagnostic accuracy were calculated by stratifying the procedures over time into six blocks of 50 (Table 1). In the absence of ROSE, sensitivity and diagnostic accuracy progressively increased according to operator experience, with values constantly >80% after the first 250 procedures.

Figure 1. Diagnostic accuracy of EUS-FNA according to subgroup considered: 12 cases performed with a change in needle during the procedure from 22- to 25-gauge, 33 cases with double simultaneous sampling in primary (P) and metastatic (M) lesions, 24 cases repeating EUS-FNA two times, and 42 cases using EUS-FNB. Number in brackets are 95% IC.
Logistic regression analysis confirmed that the variables associated with diagnostic accuracy were the endosonographer’s ability (OR = 1.21, 95% CI: 1.02–1.43, p = .03) and the simultaneous sampling of primary and metastatic lesions (OR = 9.67, 95% CI: 1.27–73.75), p = .03. An association was found between diagnostic accuracy and the use of EUS-FNB needle type, even if it did not reach statistical significance (OR = 3.06, 95% CI: 0.94–9.9, p = .06).

**Discussion**

EUS with FNA or FNB is currently the method of choice for tissue acquisition and is useful to differentiate between malignant and benign lesions in pancreas and biliary tract. When performed by an expert operator, interventional EUS has high diagnostic accuracy and a low rate of complications [9,10,21,23]. To achieve competency, a supervised training period is recommended by ESGE and ASGE guidelines, which suggest performing from 20–30 to 60 supervised EUS-FNAs to reach sufficient expertise in interventional EUS [20,21,24–26]. However, information in the literature is limited as to the best way to train future endosonographers. The exact number of procedures needed to achieve competence in EUS-FNA is difficult to establish and has not yet been sufficiently validated. Adequate EUS training is complex, expensive, and requires a long period of learning, which is not always available to an experienced operator working full time in a hospital setting. Furthermore, adequate knowledge of the pancreatic biliary anatomy and of specific diseases involving these organs [10,19–21] is required before starting EUS-FNA. In some instances, EUS training programs do not fulfill ASGE recommendations, as reported in a survey by Azad et al. [27]. The survey stated that only 48% of advanced fellows performed the minimum number of EUS procedures recommended by the ASGE. Only just over 50% of training centers had an annual EUS caseload of at least 200 procedures, which translates into the possibility to train one trainee each year [28]. Therefore, although mentored training is the best way to achieve competency in EUS-FNA, it is conceivable that a substantial proportion of endosonographers do not undergo a training program and their expertise grows through self-training. This may strongly influence the learning process in EUS-FNA techniques, signifying a long learning curve and a greater number of procedures before adequate proficiency is acquired. The impact of the operator’s ability on the diagnostic accuracy of EUS-FNA was confirmed by several investigations. Harewood et al. [17] reported that the experience of the operator is the only variable affecting the diagnostic accuracy of EUS-FNA, whilst the location and size of the lesion do not seem to influence the cellularity of the sample and pathology results. The expertise of the endosonographer is reported to affect the number of EUS-FNA passes and the safety of the procedure. In a prospective study evaluating 300 procedures performed by a single operator, the percentage of EUS-FNA with >5 passes decreased after 100 procedures and the number of complications after 200 [19]. The number of passes during EUS-FNA procedures was found to be the main factor influencing diagnostic accuracy in a series of EUS-FNAs of pancreatic and periampullary mass carried out without an on-site cytopathologist [29].

In the present study, all the procedures were performed by a single operator who had undergone training in diagnostic EUS, not including supervised EUS-FNAs. The sensitivity and diagnostic accuracy of EUS-FNA improved after the first 50 cases but reached a value >80% after 150 procedures. In this investigation, the number of procedures required to reach good diagnostic accuracy during the learning curve was greater than that reported in previous studies [17,19,21]. This discrepancy may be explained by the absence of ROSE and by the relatively limited experience of the pathologist in evaluating pancreatic FNA at the beginning of the study period. The need for a pathologist’s training must be taken into consideration in initiating the EUS FNA procedure, since
the learning curve involves both the endosonographer and the pathologist.

To overcome these limitations, as recommended by ESGE guidelines [6,21], during the same procedure a double sampling was performed, when possible, of primary and suspected metastatic lesions such as in liver or lymph nodes. Otherwise, EUS-FNA was repeated two times in the case of an inconclusive diagnosis. This working modality increased diagnostic accuracy up to >90% and proved to be useful mainly early on in the learning period.

In a large series of patients with solid pancreatic lesions, Iglesias-Garcia et al. [30] observed that the absence of ROSE was associated with a significantly higher rate of inadequate sampling, lower diagnostic sensitivity and overall accuracy for malignancy, and a greater number of passes. The influence of ROSE in determining high diagnostic accuracy of EUS-FNA was confirmed by two meta-analyses including more than 100 studies [31,32]. ROSE remained a significant determinant of EUS-FNA accuracy after correction for study population number and reference standard using meta-regression model analysis; [32] the availability of ROSE improved the adequacy rates for EUS-FNA of solid pancreatic lesions by up to 3.5% [33]. In contrast, the importance of ROSE was not confirmed in a multicenter randomized controlled trial in consecutive patients with solid pancreatic mass undergoing EUS-FNA. No difference in the diagnostic yield of malignancy was demonstrated in two study groups with and without ROSE, although in the latter group seven passes were performed [33]. In our study, the number of passes decreased during the learning period from five at the beginning to three at the end of the study period. No significant differences were observed in terms of diagnostic accuracy.

Of note, in this study EUS-FNA showed a specificity of 100%, even in the early phase, confirming that the technique is an efficient diagnostic tool providing pathological results able to differentiate pancreatic malignancies from benign lesions. As false-negative result of FNA may affect specificity, all patients with negative samples were followed up for at least 1 year to exclude the possibility of misdiagnosis.

Needle size is hypothesized to affect diagnostic accuracy according to the amount of tissue collected for cytological or histological analysis. In general, the standard needle for pancreatic EUS-FNA is a 22-gauge, but choice of needle size is guided by the presumed histological type and location of the target lesion. Ideally, a 19-gauge needle allowing the collection of a larger amount of cellular material compared to a thinner 22-gauge needle should provide a better diagnostic yield and should be preferred in the diagnosis of pancreatic tumors other than pancreatic adenocarcinoma, tumors surrounded by chronic pancreatitis, lymphoma, and autoimmune pancreatitis. However, these advantages may be offset by a higher rate of technical failures in the event of a lesion to biopsy through the second part of the duodenum. In a randomized controlled trial by Song et al. [34], technical failure using 19-gauge needles was reported in 19% of patients with pancreatic head masses. The main reason which complicates interpretation of the specimen was contamination by blood. A multicenter study showed that a thinner needle provides less cellular material than a larger one, but that the material is more easily interpreted as there is less contamination of the specimen by blood compared to sampling with a larger gauge needle. [35] Minimal differences in diagnostic accuracy between 22-gauge and 25-gauge needles are reported [35–41]. Ultrathin needles could be chosen for pancreatic tumors located in the pancreatic uncinate process because of their superior manageability, and in the case of cytological diagnosis. In the present series, a small number of procedures were carried out using a 19-gauge needle, all in the initial study period; it was therefore not possible to evaluate the difference in diagnostic accuracy between 19- and 22-gauge needles. In a small group of patients with pancreatic head lesions, changing the needle from 22- to 25-gauge during the procedure increased diagnostic accuracy in the absence of ROSE. This can be explained by the greater flexibility of thinner needles in the duodenum enabling the collection of tissue from the center of the lesion. We observed a considerable increase in diagnostic accuracy using a new FNB needle, albeit in the final part of the study period. These new needles are able to harvest a core tissue specimen with better preservation of cellular architecture than FNA needles, [42], more representative for the pathologist, and easy to interpret. Moreover, core biopsy needles procured adequate samples useful for ancillary molecular diagnosis. A further increase in diagnostic accuracy was observed using EUS-FNB [42] in the absence of ROSE. A recent study reported that EUS-FNB yielded high-quality specimens for histological diagnosis and better discrimination between pancreatic adenocarcinoma and neuroendocrine tumors [43]. The major advantage of FNB over FNA needles seems to be in the assessment of pancreatic neuroendocrine tumors before surgical resection, as they provide a greater quantity of material for Ki-67 analysis, and in the evaluation of tumor grade [44]. A comparison between needles in terms of specimen adequacy or complications was not performed in the present study due to the low number of FNB performed.

The study has some limitations. First, it is a retrospective investigation, even if data regarding the procedure and patient characteristics were prospectively recorded. The number of interventional procedures per year, especially at the beginning of the period considered, was limited and this could have contributed to extending the length of the training period. EUS-FNAs were carried out by one endosonographer, who began interventional EUS without supervised training and without the assistance of an expert pathologist in biliary-pancreatic disease. Second since most of the sampling was collected using a 22-gauge needle, there are insufficient data to quantify the influence of needle size on the diagnostic accuracy of EUS-FNA. Nevertheless, the present study provides useful insight into the learning process based on the real-life day-to-day experience of an endosonographer performing EUS in the absence of an on-site evaluation of tissue sample adequacy.

In conclusion, this study confirms that EUS-FNA and EUS-FNB are safe and efficient procedures for collecting tissue
from pancreatic mass and biliary tract with good diagnostic accuracy. Operator expertise is a crucial factor influencing the diagnostic accuracy of interventional EUS, particularly in the absence of ROSE. Whether the use of EUS-FNB is able to reduce both the time required to reach a diagnostic accuracy >85% and the number of passes needed to obtain sufficient tissue during the learning period could be the subject of a further study.

Conflict of interest: The authors have no conflicts of interest or financial ties to disclosure.

References


